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Introduction
Carbapenems are widely used in the treatment of febrile
neutropenia. However, this resulted a high rate of carba-
penem resistance in our hematopoieteic stem cell trans-
plantation (HSCT) center.
Objectives
Here, we want share the results of antibacterial usage
policy which allowed to decrease the consumption of
carbapenems.
Methods
An interventation in two stages was introduced in HSCT
center. At the first eight months of 2014, carbapenems
remained to be the first choice for febrile neutropenic
patients while the use of piperacillin/tazobactam (TZP)
was encouraged in patients with stable clinical condition.
When blood cultures were reported as negative and
patient was clinically stable the carbapenem/TZP treat-
ment was stopped regardless of continious fever and neu-
trophil count. From October 2014, TZP (with prolonged
infusion) with or without amikacin replaced carbapenems
as the first line therapy of neutropenic fever. Daily defined
dosages (DDD) per 1000 patient days were calculated for
all antibiotics by the hospital pharmacist for each year.
Results
A total of 913 admissions with 11,544 patient days were
followed in 2013; and 1,072 admissions with 11,843
patients days were followed in 2014. An increase was
observed in the rate of nosocomial pneumonia, central
line associated bacteraemia and as well as the rate of ESBL
and carbapenem resistance in gram negative bacilli
infections in 2014 when compared with 2013.
The DDDs/1000 patient days for imipenem, meropenem,
vancomycin, teicoplanin, daptomycin, linezolid, colistin,
TZP and amikacin in 2013 and 2014 were as follows; 201
vs 19; 1,578 vs1,092; 533 vs 251; 205 vs 159; 56 vs 14; 76 vs
26; 188 vs 154; 157 vs 254; and amikacin 5 vs 41.
Conclusion
Despite the rates of nosocomial infections and antibiotic
resistance increased relatively, we were able to decrease
the consumption of not only carbapenems but also glyco-
peptides. The sustainability of such intervention needs to
be monitored continuously.
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